

Mucopolidosis III alpha/beta

Description

Mucopolidosis III alpha/beta is a disorder that affects many parts of the body. Signs and symptoms of this condition typically appear around age 3 and worsen slowly over time.

Individuals with mucopolidosis III alpha/beta grow slowly and have short stature. They also have stiff joints and dysostosis multiplex, which refers to multiple skeletal abnormalities seen on x-ray. Many affected individuals develop low bone mineral density (osteoporosis), which weakens the bones and makes them prone to fracture. Osteoporosis and progressive joint problems also cause bone pain that becomes more severe over time in people with mucopolidosis III alpha/beta.

People with mucopolidosis III alpha/beta often have heart valve abnormalities and mild clouding of the clear covering of the eye (cornea). Their facial features become slightly thickened or "coarse" over time. Affected individuals may also develop frequent ear and respiratory infections. About half of people with this condition have mild intellectual disability or learning problems. Individuals with mucopolidosis III alpha/beta generally survive into adulthood, but they may have a shortened lifespan.

Frequency

Mucopolidosis III alpha/beta is a rare disorder, although its exact prevalence is unknown. It is estimated to occur in about 1 in 100,000 to 400,000 individuals worldwide.

Causes

Mutations in the *GNPTAB* gene cause mucopolidosis III alpha/beta. This gene provides instructions for making a part (subunit) of an enzyme called GlcNAc-1-phosphotransferase. This enzyme helps prepare certain newly made enzymes for transport to lysosomes. Lysosomes are compartments within the cell that use digestive enzymes to break down large molecules into smaller ones that can be reused by cells. GlcNAc-1-phosphotransferase is involved in the process of attaching a molecule called mannose-6-phosphate (M6P) to specific digestive enzymes. Just as luggage is tagged at the airport to direct it to the correct destination, enzymes are often "tagged" after they are made so they get to where they are needed in the cell. M6P acts as a tag that indicates a digestive enzyme should be transported to the lysosome.

Mutations in the *GNPTAB* gene that cause mucopolidosis III alpha/beta result in reduced

activity of GlcNAc-1-phosphotransferase. These mutations disrupt the tagging of digestive enzymes with M6P, which prevents many enzymes from reaching the lysosomes. Digestive enzymes that do not receive the M6P tag end up outside the cell, where they have increased activity. The shortage of digestive enzymes within lysosomes causes large molecules to accumulate there. Conditions that cause molecules to build up inside lysosomes, including mucopolipidosis III alpha/beta, are called lysosomal storage disorders. The signs and symptoms of mucopolipidosis III alpha/beta are most likely due to the shortage of digestive enzymes inside lysosomes and the effects these enzymes have outside the cell.

Mutations in the *GNPTAB* gene can also cause a similar but more severe disorder called mucopolipidosis II alpha/beta. These mutations completely eliminate the function of GlcNAc-1-phosphotransferase. Mucopolipidosis III alpha/beta and mucopolipidosis II alpha/beta represent two ends of a spectrum of disease severity.

[Learn more about the gene associated with Mucopolipidosis III alpha/beta](#)

- GNPTAB

Inheritance

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Other Names for This Condition

- ML III
- ML IIIA
- Mucopolipidosis III
- Mucopolipidosis III, variant
- Mucopolipidosis IIIA
- Pseudo-Hurler polydystrophy

Additional Information & Resources

Genetic Testing Information

- Genetic Testing Registry: Pseudo-Hurler polydystrophy (<https://www.ncbi.nlm.nih.gov/gtr/conditions/C0033788/>)

Genetic and Rare Diseases Information Center

- Mucopolysaccharidosis type III (<https://rarediseases.info.nih.gov/diseases/3806/index>)

Patient Support and Advocacy Resources

- National Organization for Rare Disorders (NORD) (<https://rarediseases.org/>)

Clinical Trials

- ClinicalTrials.gov (<https://clinicaltrials.gov/search?cond=%22Mucopolysaccharidosis III alpha/beta%22>)

Catalog of Genes and Diseases from OMIM

- MUCOPOLYSACCHARIDOSIS III ALPHA/BETA (<https://omim.org/entry/252600>)

Scientific Articles on PubMed

- PubMed (<https://pubmed.ncbi.nlm.nih.gov/?term=%28%28mucopolysaccharidosis+type+iii%5BTIAB%5D%29+OR+%28mucopolysaccharidosis+iii%5BTIAB%5D%29+OR+%28pseudo-hurler+polydystrophy%5BTIAB%5D%29%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+3600+days%22%5Bdp%5D>)

References

- Bargal R, Zeigler M, Abu-Libdeh B, Zuri V, Mandel H, Ben Neriah Z, Stewart F, Elcioglu N, Hindi T, Le Merrer M, Bach G, Raas-Rothschild A. When Mucopolysaccharidosis III meets Mucopolysaccharidosis II: GNPTA gene mutations in 24 patients. *Mol Genet Metab*. 2006 Aug;88(4):359-63. doi: 10.1016/j.ymgme.2006.03.003. Epub 2006 Apr 21. Erratum In: *Mol Genet Metab*. 2007 Jul;91(3):299. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/16630736>)
- Cathey SS, Kudo M, Tiede S, Raas-Rothschild A, Bräulke T, Beck M, Taylor HA, Canfield WM, Leroy JG, Neufeld EF, McKusick VA. Molecular order in mucopolysaccharidosis II and III nomenclature. *Am J Med Genet A*. 2008 Feb 15;146A(4):512-3. doi:10.1002/ajmg.a.32193. No abstract available. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/18203164>)
- Cathey SS, Leroy JG, Wood T, Eaves K, Simensen RJ, Kudo M, Stevenson RE, Friez MJ. Phenotype and genotype in mucopolysaccharidoses II and III alpha/beta: a study of 61 probands. *J Med Genet*. 2010 Jan;47(1):38-48. doi: 10.1136/jmg.2009.067736. Epub 2009 Jul 16. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/19617216>) or Free article on PubMed Central (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712854/>)
- Kudo M, Brem MS, Canfield WM. Mucopolysaccharidosis II (I-cell disease) and mucopolysaccharidosis IIIA (classical pseudo-hurler polydystrophy) are caused by mutations in the GlcNAc-

phosphotransferase alpha / beta -subunits precursor gene. *Am J Hum Genet.* 2006 Mar; 78(3):451-63. doi: 10.1086/500849. Epub 2006 Jan 24. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/16465621>) or Free article on PubMed Central (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1380288/>)

- Otomo T, Muramatsu T, Yorifuji T, Okuyama T, Nakabayashi H, Fukao T, Ohura T, Yoshino M, Tanaka A, Okamoto N, Inui K, Ozono K, Sakai N. Mucopolidosis II and III alpha/beta: mutation analysis of 40 Japanese patients showed genotype-phenotype correlation. *J Hum Genet.* 2009 Mar;54(3):145-51. doi:10.1038/jhg.2009.3. Epub 2009 Feb 6. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/19197337>)
- Steet RA, Hullin R, Kudo M, Martinelli M, Bosshard NU, Schaffner T, Kornfeld S, Steinmann B. A splicing mutation in the alpha/beta GlcNAc-1-phosphotransferase gene results in an adult onset form of mucopolidosis III associated with sensory neuropathy and cardiomyopathy. *Am J Med Genet A.* 2005 Feb 1;132A(4):369-75. doi:10.1002/ajmg.a.30498. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/15633164>)
- Tiede S, Muschol N, Reutter G, Cantz M, Ullrich K, Bräulke T. Missense mutations in N-acetylglucosamine-1-phosphotransferase alpha/beta subunit gene in a patient with mucopolidosis III and a mild clinical phenotype. *Am J Med Genet A.* 2005 Sep 1; 137A(3):235-40. doi: 10.1002/ajmg.a.30868. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/16094673>)
- Tylki-Szymanska A, Czaratoryska B, Groener JE, Lugońska A. Clinical variability in mucopolidosis III (pseudo-Hurler polydystrophy). *Am J Med Genet.* 2002 Mar 15;108(3):214-8. doi: 10.1002/ajmg.10224. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/11891688>)
- van Meel E, Qian Y, Kornfeld SA. Mislocalization of phosphotransferase as a cause of mucopolidosis III alpha/beta. *Proc Natl Acad Sci U S A.* 2014 Mar 4;111(9):3532-7. doi: 10.1073/pnas.1401417111. Epub 2014 Feb 18. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/24550498>) or Free article on PubMed Central (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3948257/>)

Last updated October 1, 2014